Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

BACKGROUND: The response rate and survival improvement for rituximab, a CD20-targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic regimens, yet relapses still occur despite treatment completion. Thus, extending...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Commun (Lond)
Main Authors: Oh, Sung Yong, Kim, Won Seog, Kim, Jin Seok, Kim, Seok Jin, Yoon, Dok Hyun, Yang, Deok-Hwan, Lee, Won Sik, Kim, Hyo Jung, Yhim, Ho-Young, Jeong, Seong Hyun, Won, Jong Ho, Lee, Suee, Kong, Jee Hyun, Lim, Sung-Nam, Ji, Jun Ho, Kwon, Kyung A., Lee, Gyeong-Won, Lee, Jae Hoon, Lee, Ho Sup, Shin, Ho-Jin, Suh, Cheolwon
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6796378/
https://ncbi.nlm.nih.gov/pubmed/31619290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-019-0403-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados